| Item Type | Name |
|
Concept
|
Actins
|
|
Concept
|
Aged, 80 and over
|
|
Concept
|
Aged
|
|
Concept
|
Complementary Therapies
|
|
Concept
|
Biology
|
|
Concept
|
Aneuploidy
|
|
Concept
|
Antimetabolites, Antineoplastic
|
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
|
Concept
|
Analysis of Variance
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Benzamides
|
|
Concept
|
Benzimidazoles
|
|
Concept
|
Cell Count
|
|
Concept
|
Cephalometry
|
|
Concept
|
Bayes Theorem
|
|
Concept
|
Bone Neoplasms
|
|
Concept
|
Azacitidine
|
|
Concept
|
Attitude to Health
|
|
Concept
|
Biopsy
|
|
Concept
|
Bridged-Ring Compounds
|
|
Concept
|
California
|
|
Concept
|
Colonic Neoplasms
|
|
Concept
|
Combined Modality Therapy
|
|
Concept
|
Imidazoles
|
|
Concept
|
DNA Repair
|
|
Concept
|
Chromosomes, Human, Pair 17
|
|
Concept
|
Insulin-Like Growth Factor II
|
|
Concept
|
Molar
|
|
Concept
|
Esophagitis
|
|
Concept
|
Insulin-Like Growth Factor I
|
|
Concept
|
Personal Satisfaction
|
|
Concept
|
Carcinoma, Hepatocellular
|
|
Concept
|
Pharmacogenetics
|
|
Concept
|
Immunohistochemistry
|
|
Concept
|
Middle Aged
|
|
Concept
|
Nigeria
|
|
Concept
|
Phenylthiohydantoin
|
|
Concept
|
Genetic Markers
|
|
Concept
|
Receptors, Androgen
|
|
Concept
|
Quinolines
|
|
Concept
|
Cohort Studies
|
|
Concept
|
Humans
|
|
Concept
|
Incisor
|
|
Concept
|
United States
|
|
Concept
|
Biomarkers, Tumor
|
|
Concept
|
Neprilysin
|
|
Concept
|
Carcinoma, Adenosquamous
|
|
Concept
|
Genes, BRCA2
|
|
Concept
|
Up-Regulation
|
|
Concept
|
Yoga
|
|
Concept
|
DNA Modification Methylases
|
|
Concept
|
Receptor, IGF Type 1
|
|
Concept
|
Postmenopause
|
|
Concept
|
Methylation
|
|
Concept
|
Apoptosis
|
|
Concept
|
Carcinoma, Lobular
|
|
Concept
|
Carcinoma, Ductal, Breast
|
|
Concept
|
Decision Support Systems, Clinical
|
|
Concept
|
Angiogenesis Inhibitors
|
|
Concept
|
BRCA1 Protein
|
|
Concept
|
Immunoconjugates
|
|
Concept
|
CpG Islands
|
|
Concept
|
Antineoplastic Agents, Hormonal
|
|
Concept
|
Insulin-Like Growth Factor Binding Protein 3
|
|
Concept
|
Meditation
|
|
Concept
|
Chemoradiotherapy, Adjuvant
|
|
Concept
|
B7-H1 Antigen
|
|
Concept
|
Genes, BRCA1
|
|
Concept
|
BRCA2 Protein
|
|
Concept
|
Promoter Regions, Genetic
|
|
Concept
|
Quinazolines
|
|
Concept
|
Senegal
|
|
Concept
|
Electron Transport Complex I
|
|
Concept
|
Meningeal Carcinomatosis
|
|
Concept
|
Cathepsin K
|
|
Concept
|
Chemoradiotherapy
|
|
Concept
|
Triazoles
|
|
Concept
|
Class I Phosphatidylinositol 3-Kinases
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Concept
|
CTLA-4 Antigen
|
|
Concept
|
Chemotherapy, Adjuvant
|
|
Concept
|
Patient Satisfaction
|
|
Concept
|
Receptor, ErbB-2
|
|
Concept
|
Telemedicine
|
|
Concept
|
DNA Methylation
|
|
Concept
|
Neoadjuvant Therapy
|
|
Concept
|
Cyclin A
|
|
Concept
|
Transcriptome
|
|
Concept
|
Vascular Endothelial Growth Factor A
|
|
Concept
|
Programmed Cell Death 1 Receptor
|
|
Concept
|
Cell Line, Tumor
|
|
Concept
|
Drug Discovery
|
|
Concept
|
Cyclin A1
|
|
Concept
|
Brain Neoplasms
|
|
Concept
|
Camptothecin
|
|
Concept
|
Communication
|
|
Concept
|
Doxorubicin
|
|
Concept
|
Follow-Up Studies
|
|
Concept
|
Kinetics
|
|
Concept
|
Longitudinal Studies
|
|
Concept
|
Lymphocytes
|
|
Concept
|
Prospective Studies
|
|
Concept
|
Retrospective Studies
|
|
Concept
|
T-Lymphocytes
|
|
Concept
|
Conserved Sequence
|
|
Concept
|
Genomics
|
|
Concept
|
Estrogen Receptor alpha
|
|
Concept
|
Proto-Oncogene Proteins c-akt
|
|
Concept
|
Young Adult
|
|
Academic Article
|
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
|
|
Academic Article
|
The molecular portraits of breast tumors are conserved across microarray platforms.
|
|
Academic Article
|
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy.
|
|
Academic Article
|
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
|
|
Academic Article
|
Advances in breast cancer: pathways to personalized medicine.
|
|
Academic Article
|
Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers.
|
|
Academic Article
|
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.
|
|
Academic Article
|
"Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
|
|
Academic Article
|
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
|
|
Academic Article
|
Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions.
|
|
Academic Article
|
Phase II trial of temsirolimus in patients with metastatic breast cancer.
|
|
Academic Article
|
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
|
|
Academic Article
|
The role of tumor-associated macrophages in breast cancer progression (review).
|
|
Academic Article
|
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
|
|
Academic Article
|
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.
|
|
Academic Article
|
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
|
|
Academic Article
|
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.
|
|
Academic Article
|
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.
|
|
Academic Article
|
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
|
|
Academic Article
|
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).
|
|
Academic Article
|
Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017.
|
|
Academic Article
|
Adaptive Randomization of Neratinib in Early Breast Cancer.
|
|
Academic Article
|
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
|
|
Academic Article
|
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
|
|
Academic Article
|
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
|
|
Academic Article
|
Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program.
|
|
Academic Article
|
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.
|
|
Academic Article
|
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing.
|
|
Academic Article
|
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
|
|
Academic Article
|
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
|
|
Academic Article
|
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.
|
|
Academic Article
|
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
|
|
Academic Article
|
Retrospective chart evaluation of hypercalcemia management in oncology patients at the University of Chicago Medical Center.
|
|
Academic Article
|
Immune Checkpoint Blockade for Breast Cancer.
|
|
Academic Article
|
Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers.
|
|
Academic Article
|
Immune Checkpoint Inhibitor Therapy in Breast Cancer.
|
|
Academic Article
|
First international TNBC conference meeting report.
|
|
Academic Article
|
Patient-provider communications about pharmacogenomic results increase patient recall of medication changes.
|
|
Academic Article
|
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.
|
|
Academic Article
|
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
|
|
Academic Article
|
Skeletal and dental changes associated with the treatment of deep bite malocclusion.
|
|
Academic Article
|
Atezolizumab for the treatment of breast cancer.
|
|
Academic Article
|
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
|
|
Academic Article
|
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
|
|
Academic Article
|
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
|
|
Academic Article
|
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
|
|
Academic Article
|
Racial disparities in survival outcomes among breast cancer patients by molecular subtypes.
|
|
Academic Article
|
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
|
|
Academic Article
|
Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial.
|
|
Academic Article
|
Novel therapies for triple-negative breast cancer.
|
|
Academic Article
|
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer.
|
|
Academic Article
|
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
|
|
Academic Article
|
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
|
|
Academic Article
|
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
|
|
Academic Article
|
The impact of site-specific digital histology signatures on deep learning model accuracy and bias.
|
|
Academic Article
|
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
|
|
Academic Article
|
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
|
|
Academic Article
|
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
|
|
Academic Article
|
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
|
|
Academic Article
|
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
|
|
Academic Article
|
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.
|
|
Academic Article
|
Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy.
|
|
Academic Article
|
Clinical trials of immunotherapy in triple-negative breast cancer.
|
|
Academic Article
|
Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform.
|
|
Academic Article
|
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.
|
|
Academic Article
|
Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy.
|
|
Academic Article
|
The evolving therapeutic landscape of antibody-drug conjugates in breast cancer.
|
|
Academic Article
|
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial.
|
|
Academic Article
|
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
|
|
Concept
|
Poly(ADP-ribose) Polymerase Inhibitors
|
|
Concept
|
Bevacizumab
|
|
Concept
|
Trastuzumab
|
|
Concept
|
Dasatinib
|
|
Concept
|
Poly (ADP-Ribose) Polymerase-1
|
|
Concept
|
Liquid Biopsy
|
|
Concept
|
Circulating Tumor DNA
|
|
Concept
|
Drug-Related Side Effects and Adverse Reactions
|
|
Concept
|
Triple Negative Breast Neoplasms
|
|
Academic Article
|
The Impact of Race and Age on Response to Neoadjuvant Therapy and Long-Term Outcomes in Black and White Women with Early-Stage Breast Cancer.
|
|
Academic Article
|
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
|
|
Academic Article
|
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence.
|
|
Academic Article
|
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer.
|
|
Academic Article
|
Demographic and Clinical Characteristics Associated With Familiarity, Interest, and Use of Integrative Therapies Among Patients With Breast Cancer.
|
|
Academic Article
|
Stress, Isolation, and Sleep Quality among Breast Cancer Survivors throughout the COVID-19 Pandemic: A Longitudinal Study in a Multi-Ethnic Cohort.
|
|
Academic Article
|
Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer.
|
|
Academic Article
|
Racial/Ethnic Disparities in Telemedicine Utilization and Satisfaction Among Breast Cancer Patients During the COVID-19 Pandemic: A Mixed-Methods Analysis.
|
|
Academic Article
|
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
|
|
Academic Article
|
Validation of the RSClin risk calculator in the National Cancer Data Base.
|
|
Academic Article
|
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
|
|
Academic Article
|
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
|